RISK WARNING
All VCT, EIS, SEIS, and Business Relief qualifying investments are high risk and are not suitable for most clients. They are illiquid investments and Investors’ capital is at risk.

Deepbridge Life Sciences EIS

Investment Objective

The investment strategy of the Deepbridge Life Sciences EIS is to invest in a diversified portfolio of up to ten investee companies that participate in one of the following: Biopharmaceuticals; Biotechnology; or Medical Technology.The Deepbridge Life Sciences Team seeks to invest in companies that possess some or all of the following attributes:

  • A focus on life sciences and medical device technology;
  • Significant market potential with clear need and market growth;
  • Provide a solution to a recognised clinical or healthcare need;
  • Innovation-driven products that have the potential to create new market segments or displace current technologies;
  • Medical technology businesses with a clear and realistic path to commercialisation;
  • Robust intellectual property which may provide patented or patentable IP protection;
  • Passionate, energetic, experienced and aligned founding team;
  • Clear exit strategy to be implemented within 4-5 years with alignment of interests with our stakeholders.

Please note that not all attributes may be achievable in each investment.

Exit Strategy

The Deepbridge Team believes that most exits in the technology sector will take place in the M&A space, and so aim to execute business models suitable for this exit route. The Deepbridge team will assess any opportunity to capitalise on exit opportunities, notwithstanding the 3 year EIS period, if an early exit is in investors’ best interests.

Deepbridge believes that either a sale of the investee companies, or a sale or refinancing of the assets owned by the investee companies, will enable funds to be returned to Investors.

Fund Manager

AUM: £166m
DATE OF FCA AUTHORISATION: 03 December 2020

Fees

Fee typeFees charged to the
investor
(including VAT)
Fees charged to Investee
Companies
(including VAT)
Initial Feen /a6.00%
Annual Management Feen /a2.40%
Performance Fee20%*n/a
Other Fee Informationn /a0.50% - Custodian Fee
*Performance Incentive Fee: Once the investor has received in cash the first 120 pence per 100 pence invested (ignoring any tax relief and representing a 20% hurdle rate on funds invested).

For further information please do not hesitate to contact us on:
+44 (0) 20 7952 6685
info@kuberventures.com
www.kuberventures.co.uk

Fund at a glance

Scheme Categorisation

Alternative Investment Fund

Launch Date

01 March 2017

Investment Sector

Life Sciences

Scheme Strategy

Private Equity

Target Return

£1.70 for every £1 invested

Target Diversification

3 - 8 investee companies

Nominee & Custody Arrangements

Custodian: Woodside Corporate Services Ltd

Nominee: WCS Nominees Ltd